Drug intelligence / Profile preview

Clostridioides difficile vaccine formulation 3

Development stage: Unknown
Lead developer: Pfizer
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Clostridioides difficile vaccine formulation 3 is a toxoid-based vaccine developed by Pfizer. It is designed to prevent severe diarrhea caused by Clostridioides difficile (C. diff) infection by inducing an antibody response. This specific formulation is being evaluated in a Phase 1/2 randomized study to assess its safety, tolerability, immunogenicity, and immunopersistence in healthy adults, comparing it to a previously studied C. diff vaccine formulation.

Other names: C. difficile vaccine formulation 3

Targets

GTD (Clostridioides difficile toxin glucosyltransferase domain)

Beyond the preview

Go deeper on Clostridioides difficile vaccine formulation 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clostridioides difficile vaccine formulation 3.

Explore the full profile